1527P - Small cell lung cancer (SCLC) treated in first line with hybrid scheme with carboplatin and etoposide intravenous (IV) and oral. Comparison between...

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Anti-Cancer Agents & Biologic Therapy
Small-Cell Lung Cancer
Presenter Andrea Ruiz-Valdepeñas
Authors A. Ruiz-Valdepeñas1, M. Palka1, E. Almagro Casado1, D. Pérez Callejo2, P. Ibeas3, B.G. Doger de Speville4, C. Maximiano1, B. Cantos1, G. Diaz5, M. Provencio Pulla6
  • 1Medical Oncology, Hospital Universitario Puerta de Hierro Majadahonda, 28222 - Madrid/ES
  • 2Hospital Universitario Puerta de Hierro Majadahonda, 28222 - Madrid/ES
  • 3Clinical Oncology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, 28220 - Majadahonda/ES
  • 4Medical Oncology, Hospital Universitario Puerta de Hierro, 28222 - Majadahonda/ES
  • 5Neumology, Hospital Universitario Puerta de Hierro, 28222 - Majadahonda/ES
  • 6Oncology, Hospital Universitario Puerta de Hierro Majadahond, 28222 - Majadahonda/ES

Abstract

Introduction

The current increase in longevity with a good quality of life in old people, and the prevalence of SCLC in this population, makes necessary an effective and safe treatment to face it. The aims of this study are to evaluate if there are differences in overall survival and toxicity according to the age (comparing older and younger than 65 years old), in patients treated with Carboplatin 300mg/m2 iv on day 1, and Etoposid 100mg/m2 per day (iv on day 1 and oral on days 2 to 5).

Material and methods

Medical records of patients diagnosed of SCLC between years 2003 and 2010 and treated in our Hospital by the scheme Carboplatin 300mg/m2 iv on day 1, with Etoposid 100mg/m2 per day (iv on day 1 and oral days two to five), were retrospective reviewed. Patient's characteristics, overall survival and causes of death were obtained and analyzed by group of age (patients until 65 years old and older).

Results

96 patients diagnosed of SCLC between January of 2003 and August of 2010 were treated in our Hospital with the aforementioned scheme of chemotherapy. Seventy of them were Extended Stage, and 26 Limited Stage; 54 were until 65 years old (56.25%) and 42 were older (43.75%). Differences in overall survival were not founded between group of older and younger of 65 years old, in both limited and extended stage. In Extended disease, the elder than 65 years old presented a median overall survival of 10 months (1-22), and the younger than 65 had a median overall survival was 8.23 months, (<1-24). In the group with Limited stage, the median overall survival in older than 65 was 11.5 months (6-81), and for the younger 15 months (4-25). Most of patients died due to tumour progression, but in 6 patients this was caused by thromboembolism, infections, or toxicity due to treatment (in 2 patients, 1 in each group of age), all of them without differences by group of age.

Conclusion

In SCLC, hybrid scheme Carboplatin 300mg/m2 iv on day 1, with Etoposid 100mg/m2 per day, iv on day 1 and oral days 2 to 5, provides an acceptable overall survival and toxicity, without significant differences comparing older and younger than 65 years old, both in Limited and Extended Stage.

Disclosure

All authors have declared no conflicts of interest.